Abstract:PurposeTo compare gadobutrol and gadopentetate dimeglumine (Gd-DTPA) contrast-enhanced magnetic resonance imaging (MRI) at 3T for visualizing brain metastases. Materials and MethodsThe present randomized study included 60 consecutive patients with known or suspected brain metastases from systemic malignancies. Two enhanced cerebral MR scans were performed in each patient within an interval of 2-5 days using different contrast agents (gadobutrol or Gd-DTPA) at 3T. The dose of the contrast agents (0.1 mmol/kg Gd) was also identical. The axial T-1 FLAIR images at 3, 7, and 10 minutes after the injection of the contrast agent were obtained for evaluation. Two experienced radiologists performed subjective evaluation of the image quality, made the choice of the optimal images, and performed an objective evaluation including: signal-to-noise ratio (SNR) of the brain metastases, contrast-to-noise ratio (CNR), contrast enhancement (CE), contrast-to-brain ratio (CBR), and contrast enhancement ratio (CER) of the brain metastases. ResultsSubjective evaluation showed that at 3, 7, and 10 minutes gadobutrol elicited higher scores (margin score: 3.560.74 vs. 3.330.93, 3.680.57 vs. 3.45 +/- 0.81, 3.58 +/- 0.71 vs. 3.43 +/- 0.76; interior score: 2.83 +/- 0.42 vs. 2.63 +/- 0.61, 2.86 +/- 0.38 vs. 2.73 +/- 0.52, 2.80 +/- 0.42 vs. 2.69 +/- 0.53; and overall score: 4.42 +/- 0.98 vs. 4.09 +/- 1.19, 4.57 +/- 0.75 vs. 4.26 +/- 1.05, 4.48 +/- 0.83 vs. 4.21 +/- 1.03, respectively) in displaying the details and overall lesions than Gd-DTPA (repeated measures analysis of variance [ANOVA], margin score: P=0.001, < 0.0001, 0.006; interior score: P < 0.0001, 0.004, 0.009; and overall score: P=0.001, < 0.0001, < 0.0001, respectively). Subjective optimal image evaluation showed that the percentage of image assessed as gadobutrol was better than Gd-DTPA (41.2-44.1%) was greater than that assessed as Gd-DTPA was better than gadobutrol (5.9-26.5%). Objective evaluation showed that at 3, 7, and 10 minutes the SNR (214.17 +/- 85.70 vs. 199.57 +/- 85.08, 214.80 +/- 86.03 vs. 199.19 +/- 84.74, and 213.83 +/- 82.46 vs. 193.68 +/- 79.59, respectively), CNR (68.64 +/- 50.18 vs. 57.88 +/- 51.06, 75.42 +/- 53.19 vs. 63.74 +/- 53.91, and 77.13 +/- 51.86 vs. 63.21 +/- 51.71, respectively), CE (101.76 +/- 63.31 vs. 87.61 +/- 64.85, 99.85 +/- 61.56 vs. 85.08 +/- 64.98, and 100.33 +/- 58.63 vs. 82.73 +/- 61.73, respectively), CBR (0.48 +/- 0.32 vs. 0.40 +/- 0.33, 0.54 +/- 0.34 vs. 0.46 +/- 0.35, and 0.56 +/- 0.34 vs. 0.47 +/- 0.34, respectively), and CER (0.99 +/- 0.69 vs. 0.88 +/- 0.81, 0.97 +/- 0.68 vs. 0.86 +/- 0.84, and 0.98 +/- 0.65 vs. 0.85 +/- 0.80, respectively) were all higher when using gadobutrol compared with Gd-DTPA in the enhanced MR (repeated measures ANOVA, all P < 0.0001). On Gd-DTPA enhanced images, 289, 292, and 292 lesions at 3, 7, and 10 minutes were detected by the two radiologists, while 295, 301, and 301 lesions were detected on gadobutrol-enhanced images, respectively. ConclusionUsing a 3T T-1 FLAIR sequence, gadobutrol (0.1 mmol/kg body weight)-enhanced MR resulted in more conspicuous brain metastases, and more metastases compared with the same dose of Gd-DTPA. A delay time of 7 minutes for postcontrast MRI in patients with brain metastases is suggested in clinical practice.

The effects of three different contrast agents (Gd-BOPTA, Gd-DTPA, and Gd-DOTA) on brachial plexus magnetic resonance imaging

Post-Contrast 3D Inversion Recovery Magnetic Resonance Neurography for Evaluation of Branch Nerves of the Brachial Plexus

Three dimensional sampling perfection with application-optimized contrasts by using different flip angle evolutions-short time of the inversion recovery sequence for the post-ganglionic segments of the brachial plexus

Enhanced MR neurography of the lumbosacral plexus with robust vascular suppression and improved delineation of its small branches.

Intraindividual In Vivo Comparison Of Gadolinium Contrast Agents For Pharmacokinetic Analysis Using Dynamic Contrast Enhanced Magnetic Resonance Imaging

Effect Of Intravenous Gadolinium-Dtpa On Diffusion-Weighted Imaging For Prostate Lesions And Normal Tissue At 3.0-Tesla Magnetic Resonance Imaging

MRI of sacral plexus：three-dimensional sampling perfection with application optimized contrasts using different lfip angle evolutions versus three-dimensional double-echo steady state

The Development of Dendritic Gd-Dtpa Complexes for Mri Contrast Agents

Efficacy of Gadobenate Dimeglumine Vs Gadopentetate Dimeglumine in Contrastenhanced Magnetic Resonance Imaging for Diagnosis of Solitary Brain Metastases

Improved Display of Abdominal Contrast-Enhanced MRA Using Gadobutrol: Comparison with Gd-DTPA.

3D MR neurography with gadolinium contrast to improve the visualization of pelvic nerves and the branches

Gadolinium(III) Complex-Backboned Branched Polymers As Imaging Probes for Contrast-Enhanced Magnetic Resonance Angiography

Low-dose Contrast-Enhanced Magnetic Resonance Imaging of Brain Metastases at 3.0 T Using High-Relaxivity Contrast Agents.

Gastrointestinal Contrast Agents for Improving Imaging Quality of MRCP: Comparison Between Gd-DTPA and BaSO4 Suspension

Diagnostic Value and Surgical Implications of the 3D DW-SSFP MRI On the Management of Patients with Brachial Plexus Injuries

Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.

Intra-Individual Comparison of Different Gadolinium-Based Contrast Agents in the Quantitative Evaluation of C6 Glioma with Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Gadobutrol Precedes Gd-DTPA in Abdominal Contrast-Enhanced MRA and MRI: A Prospective, Multicenter, Intraindividual Study.

Diagnostic contribution of contrast-enhanced 3D MR imaging of peripheral nerve pathology

Application of Enhanced MR (3.0T) Scanning with 3D-SPACE-STIR Sequence for Postganglionic Neurogenic Tumors of the Brachial Plexus

A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.